


HEALTHCARE

Next-Generation Nutraceuticals

Food and pharma convergence in disease prevention and personalized nutrition

By Dr CL Barton

 [Table of Contents](#)

Dr Cheryl L Barton

Dr CL Barton worked for over 10 years in pharmaceutical and nutraceutical research, followed by comprehensive experience as a Pan-European Pharmaceutical analyst with a European Bank.

Dr CL Barton Ltd. aims to provide independent, tailor-made, pharmaceutical and nutraceutical thematic research to investment houses. Where applicable the research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and isolate the key drivers within the pharmaceutical sector. For more details visit www.pharmavision.co.uk

Copyright © 2006 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Next-Generation Nutraceuticals

Executive Summary	10	
Food and pharmaceutical disease prevention	10	
Functional food and drinks	11	
Technologies for nutrigenomics	12	
The regulatory landscape	13	
Strategies of leading ingredient, food, drinks and pharma companies	14	
Future challenges and opportunities	15	
Chapter 1	Food and pharmaceutical disease prevention	18
Summary		18
Introduction		19
The changing approach to the health burden		20
New technologies		22
Key convergent markets		22
Obesity		24
Epidemiology		24
Sales		25
Cardiovascular disease		27
Epidemiology		27
Sales		29
Diabetes		31
Epidemiology		31
Sales		31
Bone health		33
Epidemiology		33
Sales		34
Conclusions		36

Chapter 2 Functional food and drinks 38

Summary	38
Introduction	39
Functional food and drinks	40
Functional ingredients	40
Scientific evidence to support the health benefits of functional ingredients	42
Proving efficacy: pharma vs. food	44
Growth areas and product trends in the functional foods market	45
Heart health	47
Digestive health - Probiotics	50
Innovative ingredients aligning with pharma	53
Personalized nutrition	54
Conclusions	55

Chapter 3 Technologies for nutrigenomics 58

Summary	58
Introduction	59
Biomic technologies in the pharma industry	59
Pharma technologies in the food industry	61
Genomics	63
Genomics in personalized nutrition	64
Case study: Sciona Inc	66
Transcriptomics	69
Transcriptomics in the food industry	71
Case study: WellGen Inc.	72
Proteomics	74
Metabolomics	75
Case study: the INTERMAP study	76
Challenges to metabolomics in nutrition research	77
Growth and interest in metabolomics	77
Systems Biology	78
Nanotechnology delivering new ingredients	79
Conclusions	80

Chapter 4 The regulatory landscape 82

Summary	82
Introduction	83

List of Figures

Figure 1.1:	Drivers of change in the food and pharma industries	19
Figure 1.2:	Examples of food and pharma approaches to heart disease	21
Figure 1.3:	A functional food pyramid	23
Figure 1.4:	The role of food and pharmaceuticals in the healthcare continuum	23
Figure 1.5:	Examples of obesity drugs in development	26
Figure 1.6:	Global deaths from cardiovascular disease	27
Figure 1.7:	Drugs in clinical development for CV disorders	30
Figure 2.8:	Top US consumer health concerns, 2005	46
Figure 2.9:	Nutrigen IQ3 Yogurt Drink	48
Figure 2.10:	Right Direction Cookies	49
Figure 2.11:	DanaCol with Omega-3 & Plant Sterols Dairy Drink	50
Figure 2.12:	Calpis Aqua Nyusankin	51
Figure 2.13:	Calpis Interbalance L-92 Lactic Acid Bacteria Drink	53
Figure 3.14:	The ‘omics technologies: definitions	60
Figure 3.15:	The ‘omics technologies	61
Figure 3.16:	The Cellf™ Assessment Kit from Sciona	66
Figure 3.17:	Pro-inflammatory metabolic pathways	73
Figure 3.18:	Technologies used in proteomics	74
Figure 3.19:	¹ H NMR spectrum of urine showing functional windows	75
Figure 3.20:	Large scale metabolomic screening of human populations: identifying outliers	76
Figure 4.21:	Standardized qualifying language for qualified health claims	88
Figure 4.22:	Examples of structure/function claims allowed on food labeling	89
Figure 5.23:	Recent products launched that contain TEAVIGO™	102
Figure 5.24:	Development of new probiotic cultures at Chr. Hansen	105
Figure 5.25:	Nestlé’s products by functional category, 2004-2006	108
Figure 5.26:	Nestlé’s functional brands (2005)	109
Figure 5.27:	Nestle NesVita Pro-Heart Probiotic Drink	110
Figure 5.28:	Unilever’s products by functional category, 2004-2006	112
Figure 5.29:	Flora Pro-Active Blood Pressure Mini Drink	113
Figure 5.30:	Ajinomoto products by functional category, 2004-2006	115
Figure 5.31:	Calpis Ameal S Maiasa Yasai (vegetable breakfast drink)	117
Figure 5.32:	Danone’s products by functional category, 2004-2006	118
Figure 5.33:	Danone Petit Danone Cheese Dessert	119
Figure 5.34:	Coca-Cola’s products by functional category, 2004-2006	120
Figure 5.35:	Enviga	121
Figure 5.36:	Novartis’ Benefiber Clear Choice! Powder and Isocal Jelly Arg Jelly Dessert	126
Figure 6.37:	Awareness and favorability towards personalized nutrition	138

List of Tables

Table 1.1:	Number and percentage of overweight and obese adults by country, 2005-2010 (% adult population)	24
Table 1.2:	Size of the diet food and drinks market and the obesity pharmaceutical market, (US\$,m), 2005-2010	25
Table 1.3:	Estimated prevalence of major cardiovascular diseases in the seven major markets, 2004	28
Table 1.4:	Size of the food and drinks and pharmaceutical markets for heart health, (US\$,m), 2005-2010	29
Table 1.5:	Prevalence of type-2 diabetes in the 7 major markets, 2005-11	31
Table 1.6:	Size of the pharmaceutical market for diabetes, (US\$,m), 2005-2010	32
Table 1.7:	Prevalence of Rheumatoid Arthritis based on population > 60 in the seven major markets (000s), 2005–2010	33
Table 1.8:	Prevalence of osteoporosis in men and women over 50 across the seven major markets, 2005	34
Table 1.9:	Size of the food and drinks and pharmaceutical markets for bone health, (US\$m), 2005-2010	35
Table 2.10:	Functional ingredients	40
Table 2.11:	Functional food ingredients (cont.)	41
Table 2.12:	Examples of functional food ingredients and the scientific basis for health benefit claims	43
Table 2.13:	Functional food and drink sales by value (\$m), 2005-2008	45
Table 3.14:	Companies offering nutrigenetic testing and dietary advice, 2006	65
Table 3.15:	Genetic variations screened by the Cellf™ Assessment Kit from Sciona, 2006	67
Table 3.16:	How nutrients alter gene expression	69
Table 3.17:	Examples of transcriptomics in nutritional biology and nutrigenomics	70
Table 3.18:	Companies and research centres utilizing gene expression analysis for nutrigenomic applications	71
Table 4.19:	FOSHU functions and functional food components	85
Table 4.20:	Generic health claims currently approved by the FDA	87
Table 4.21:	Regulatory opportunities and threats in the functional foods industry	92
Table 5.22:	Ajinomoto products containing AmealPeptide™ launched in Japan	116
Table 5.23:	Recent functional food and drinks launches	122
Table 5.24:	Some functional food and drink products launched by pharma companies	124
Table 5.25:	Consortia involved in the International Nutrigenomics Network	132
Table 5.26:	Examples of other collaborative nutrigenomic research projects	133
Table 6.27:	Biomarkers for well-being and disease risk reduction	143